{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:49:38Z","timestamp":1793504978571,"version":"4.5.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02608-5","type":"journal-article","created":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T10:57:06Z","timestamp":1738493826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Sheeri","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,2]]},"reference":[{"issue":"1","key":"2608_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21332.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2608_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5144\/0256-4947.2005.1","volume":"25","author":"I Maghfoor","year":"2005","unstructured":"Maghfoor I, Perry MC. Lung cancer. Ann Saudi Med. 2005;25(1):1\u201312. https:\/\/doi.org\/10.5144\/0256-4947.2005.1.","journal-title":"Ann Saudi Med"},{"issue":"12","key":"2608_CR3","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1158\/0008-5472.CAN-19-0458","volume":"79","author":"DR Welch","year":"2019","unstructured":"Welch DR, Hurst DR. Defining the hallmarks of metastasis. Can Res. 2019;79(12):3011\u201327.","journal-title":"Can Res"},{"issue":"2","key":"2608_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/cancers14020280","volume":"14","author":"V Jacquemin","year":"2022","unstructured":"Jacquemin V, Antoine M, Dom G, Detours V, Maenhaut C, Dumont JE. Dynamic cancer cell heterogeneity: diagnostic and therapeutic implications. Cancers. 2022;14(2):280.","journal-title":"Cancers"},{"issue":"4","key":"2608_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u201328.","journal-title":"Cell"},{"issue":"6","key":"2608_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational implications of tumor heterogeneity. Clin Cancer Res. 2015;21(6):1258\u201366.","journal-title":"Clin Cancer Res"},{"issue":"6206","key":"2608_CR7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1256930","volume":"346","author":"J Zhang","year":"2014","unstructured":"Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014;346(6206):256\u20139.","journal-title":"Science"},{"key":"2608_CR8","unstructured":"Global Cancer Observatory. Available online: https:\/\/gco.iarc.fr (accessed on 30 December 2020)"},{"issue":"8","key":"2608_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jtho.2021.02.004","volume":"16","author":"N Singh","year":"2021","unstructured":"Singh N, Agrawal S, Jiwnani S, Khosla D, Malik PS, Mohan A, Penumadu P, Prasad KT. Lung cancer in India. J Thorac Oncol. 2021;16(8):1250\u201366. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.004.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2608_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/ijms22020612","volume":"22","author":"SS Fois","year":"2021","unstructured":"Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 2021;22(2):612. https:\/\/doi.org\/10.3390\/ijms22020612.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2608_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3978\/j.issn.2072-1439.2013.08.03","volume":"5","author":"WA Cooper","year":"2013","unstructured":"Cooper WA, Lam DC, O\u2019Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013;5(5):479\u201390. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.08.03.","journal-title":"J Thorac Dis"},{"issue":"1","key":"2608_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4062\/biomolther.2017.211","volume":"26","author":"HY Min","year":"2018","unstructured":"Min HY, Lee HY. Oncogene-driven metabolic alterations in cancer. Biomol Ther (Seoul). 2018;26(1):45\u201356. https:\/\/doi.org\/10.4062\/biomolther.2017.211.","journal-title":"Biomol Ther (Seoul)"},{"key":"2608_CR13","unstructured":"US Department of Health and Human Services. The health consequences of smoking\u201450 years of progress: a report of the Surgeon General."},{"issue":"18","key":"2608_CR14","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1002\/cncr.28749","volume":"120","author":"DR Lewis","year":"2014","unstructured":"Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer. 2014;120(18):2883\u201392. https:\/\/doi.org\/10.1002\/cncr.28749.","journal-title":"Cancer"},{"issue":"6","key":"2608_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519.","journal-title":"J Gen Physiol"},{"key":"2608_CR16","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7013.1000211","author":"VK Ramanujan","year":"2015","unstructured":"Ramanujan VK. Metabolic plasticity in cancer cells: reconnecting mitochondrial function to cancer control. J Cell Sci Ther. 2015. https:\/\/doi.org\/10.4172\/2157-7013.1000211.","journal-title":"J Cell Sci Ther"},{"issue":"1","key":"2608_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2608_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12943-018-0901-2","volume":"17","author":"CM Schaal","year":"2018","unstructured":"Schaal CM, Bora-Singhal N, Kumar DM, Chellappan SP. Regulation of Sox2 and stemness by nicotine and electronic cigarettes in non-small cell lung cancer. Mol Cancer. 2018;17(1):149. https:\/\/doi.org\/10.1186\/s12943-018-0901-2.","journal-title":"Mol Cancer"},{"key":"2608_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/1758834013517413","volume":"6","author":"N Asai","year":"2014","unstructured":"Asai N, Ohkuni Y, Kaneko N, Yamaguchi E, Kubo A. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol. 2014;6:69\u201382. https:\/\/doi.org\/10.1177\/1758834013517413.","journal-title":"Ther Adv Med Oncol"},{"key":"2608_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive-stage small-cell lung cancer: a phase 3 randomized controlled trial. Lancet. 2015;385:36\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(14)61085-0.","journal-title":"Lancet"},{"issue":"1","key":"2608_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3978\/j.issn.2218-6751.2016.01.13","volume":"5","author":"G Alvarado-Luna","year":"2016","unstructured":"Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? A review. Transl Lung Cancer Res. 2016;5(1):26\u201338. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2016.01.13.","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"2608_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","volume":"28","author":"MB Schabath","year":"2019","unstructured":"Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomark Prev. 2019;28(10):1563\u201379. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0221.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"4","key":"2608_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","volume":"12","author":"M Chevallier","year":"2021","unstructured":"Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217\u201337. https:\/\/doi.org\/10.5306\/wjco.v12.i4.217.","journal-title":"World J Clin Oncol"},{"issue":"9","key":"2608_CR24","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170070","volume":"7","author":"S Blandin Knight","year":"2017","unstructured":"Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9): 170070. https:\/\/doi.org\/10.1098\/rsob.170070.","journal-title":"Open Biol"},{"issue":"8","key":"2608_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032899","volume":"102","author":"Y Alduais","year":"2023","unstructured":"Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine. 2023;102(8): e32899.","journal-title":"Medicine"},{"issue":"16","key":"2608_CR26","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3889\/oamjms.2019.410","volume":"7","author":"NN Soeroso","year":"2019","unstructured":"Soeroso NN, Afiani D, Tarigan SP, Qodry F. The characteristic of secondary lung tumors in medan. Open Access Macedonian J Med Sci. 2019;7(16):2623.","journal-title":"Open Access Macedonian J Med Sci"},{"key":"2608_CR27","unstructured":"Macmilan Cancer Support England and wales company. Lung metastases cancer. Macmilan Cancer Support. 2015"},{"issue":"1","key":"2608_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/SLA.0000000000003393","volume":"271","author":"H Raskov","year":"2020","unstructured":"Raskov H, S\u00f8by JH, Troelsen J, Bojesen RD, G\u00f6genur I. Driver gene mutations and epigenetics in colorectal cancer. Ann Surg. 2020;271(1):75\u201385.","journal-title":"Ann Surg"},{"issue":"12","key":"2608_CR29","doi-asserted-by":"publisher","first-page":"1042196","DOI":"10.3389\/fonc.2022.1042196","volume":"22","author":"SH Alshahrani","year":"2022","unstructured":"Alshahrani SH, Ibrahim YS, Jalil AT, Altoum AA, Achmad H, Zabibah RS, Gabr GA, Ram\u00edrez-Coronel AA, Alameri AA, Qasim QA, Karampoor S. Metabolic reprogramming by miRNAs in the tumor microenvironment: focused on immunometabolism. Front Oncol. 2022;22(12):1042196.","journal-title":"Front Oncol"},{"issue":"138","key":"2608_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111450","volume":"1","author":"S Xie","year":"2021","unstructured":"Xie S, Wu Z, Qi Y, Wu B, Zhu X. The metastasizing mechanisms of lung cancer: recent advances and therapeutic challenges. Biomed Pharmacother. 2021;1(138): 111450.","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"2608_CR31","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.3390\/ijms21134569","volume":"21","author":"K Wadowska","year":"2020","unstructured":"Wadowska K, Bil-Lula I, Trembecki \u0141, \u015aliwi\u0144ska-Mosso\u0144 M. Genetic markers in lung cancer diagnosis: a review. Int J Mol Sci. 2020;21(13):4569. https:\/\/doi.org\/10.3390\/ijms21134569.","journal-title":"Int J Mol Sci"},{"key":"2608_CR32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12254-017-0361-1","volume":"10","author":"L M\u00fcllauer","year":"2017","unstructured":"M\u00fcllauer L. Next generation sequencing: clinical applications in solid tumors. Memo. 2017;10:244\u20137. https:\/\/doi.org\/10.1007\/s12254-017-0361-1.","journal-title":"Memo"},{"issue":"2","key":"2608_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mpmed.2019.11.001","volume":"48","author":"P Nenclares","year":"2020","unstructured":"Nenclares P, Harrington KJ. The biology of cancer. Medicine. 2020;48(2):67\u201372. https:\/\/doi.org\/10.1016\/j.mpmed.2019.11.001.","journal-title":"Medicine"},{"issue":"5","key":"2608_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.17219\/acem\/68631","volume":"27","author":"AM Romaszko","year":"2018","unstructured":"Romaszko AM, Doboszy\u0144ska A. Multiple primary lung cancer: a literature review. Adv Clin Exp Med. 2018;27(5):725\u201330. https:\/\/doi.org\/10.17219\/acem\/68631.","journal-title":"Adv Clin Exp Med"},{"issue":"1","key":"2608_CR35","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2608_CR36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","volume":"2","author":"N Rivlin","year":"2011","unstructured":"Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466\u201374. https:\/\/doi.org\/10.1177\/1947601911408889.","journal-title":"Genes Cancer"},{"issue":"5","key":"2608_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/JTO.0b013e31824cc334","volume":"7","author":"RS Heist","year":"2012","unstructured":"Heist RS, Sequist LV, Engelman JA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. 2012;7(5):924\u201333. https:\/\/doi.org\/10.1097\/JTO.0b013e31824cc334.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2608_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med. 2016;6(3): a026104. https:\/\/doi.org\/10.1101\/cshperspect.a026104.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"2608_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.648808","volume":"18","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liu J, Wang J, Zhang T, Xu D, Hu W, Feng Z. The interplay between tumor suppressor p53 and hypoxia signaling pathways in cancer. Front Cell Dev Biol. 2021;18(9): 648808.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"2608_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","volume":"12","author":"C Zhang","year":"2020","unstructured":"Zhang C, Liu J, Xu D, Zhang T, Hu W, Feng Z. Gain-of-function mutant p53 in cancer progression and therapy. J Mol Cell Biol. 2020;12(9):674\u201387.","journal-title":"J Mol Cell Biol"},{"issue":"21","key":"2608_CR41","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.3390\/ijms21218387","volume":"21","author":"J Liu","year":"2020","unstructured":"Liu J, Zhang C, Wang J, Hu W, Feng Z. The regulation of ferroptosis by tumor suppressor p53 and its pathway. Int J Mol Sci. 2020;21(21):8387.","journal-title":"Int J Mol Sci"},{"key":"2608_CR42","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20:815.","journal-title":"Curr Top Med Chem"},{"issue":"4\u20135","key":"2608_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","volume":"27","author":"S Halder","year":"2023","unstructured":"Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P. Targeting the EGFR signaling pathway in cancer therapy: what\u2019s new in 2023? Expert Opin Ther Targets. 2023;27(4\u20135):305\u201324.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"2608_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yexcr.2018.08.009","volume":"371","author":"RA Mitchell","year":"2018","unstructured":"Mitchell RA, Luwor RB, Burgess AW. Epidermal growth factor receptor: structure-function informing the design of anticancer therapeutics. Exp Cell Res. 2018;371(1):1\u20139.","journal-title":"Exp Cell Res"},{"key":"2608_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a020768","author":"MA Lemmon","year":"2014","unstructured":"Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harbor Perspect Biol. 2014. https:\/\/doi.org\/10.1101\/cshperspect.a020768.","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"2608_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","volume":"79","author":"R Roskoski Jr","year":"2014","unstructured":"Roskoski R Jr. The ErbB\/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34\u201374. https:\/\/doi.org\/10.1016\/j.phrs.2013.11.002.","journal-title":"Pharmacol Res"},{"key":"2608_CR47","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s00109-005-0699-4","volume":"83","author":"H Sihto","year":"2005","unstructured":"Sihto H, Puputti M, Pulli L, Tynninen O, Koskinen W, Aaltonen LM, Tanner M, B\u00f6hling T, Visakorpi T, B\u00fctzow R, Knuuttila A. Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J Mol Med. 2005;83:976\u201383.","journal-title":"J Mol Med"},{"issue":"102","key":"2608_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2016.10.010","volume":"1","author":"AM Chapman","year":"2016","unstructured":"Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;1(102):122\u201334.","journal-title":"Lung Cancer"},{"issue":"5","key":"2608_CR49","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H. Differential sensitivity of glioma-versus lung cancer\u2013specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458\u201371.","journal-title":"Cancer Discov"},{"issue":"11","key":"2608_CR50","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/nm.3388","volume":"19","author":"CR Chong","year":"2013","unstructured":"Chong CR, J\u00e4nne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389\u2013400.","journal-title":"Nat Med"},{"issue":"1","key":"2608_CR51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4062\/biomolther.2017.211","volume":"26","author":"HY Min","year":"2018","unstructured":"Min HY, Lee HY. Oncogene-driven metabolic alterations in cancer. Biomol Ther. 2018;26(1):45.","journal-title":"Biomol Ther"},{"issue":"2","key":"2608_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5732\/cjc.012.10098","volume":"32","author":"PM Westcott","year":"2013","unstructured":"Westcott PM, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer. 2013;32(2):63.","journal-title":"Chin J Cancer"},{"issue":"17","key":"2608_CR53","first-page":"4682","volume":"49","author":"JL Bos","year":"1989","unstructured":"Bos JL. Ras oncogenes in human cancer: a review. Can Res. 1989;49(17):4682\u20139.","journal-title":"Can Res"},{"issue":"10","key":"2608_CR54","doi-asserted-by":"publisher","first-page":"1033348","DOI":"10.3389\/fcell.2022.1033348","volume":"1","author":"C Nuevo-Tapioles","year":"2022","unstructured":"Nuevo-Tapioles C, Philips MR. The role of KRAS splice variants in cancer biology. Front Cell Dev Biol. 2022;1(10):1033348.","journal-title":"Front Cell Dev Biol"},{"key":"2608_CR55","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbamcr.2016.01.025","volume":"4","author":"J Paluncic","year":"2016","unstructured":"Paluncic J, Kovacevic Z, Jansson PJ, Kalinowski D, Merlot AM, Huang ML, Lok HC, Sahni S, Lane DJ, Richardson DR. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta Mol Cell Res. 2016;4:770\u201384.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"1","key":"2608_CR56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/curroncol30010027","volume":"30","author":"A Avil\u00e9s-Salas","year":"2022","unstructured":"Avil\u00e9s-Salas A, D\u00edaz-Garc\u00eda DA, Lara-Mej\u00eda L, Cardona AF, Orozco-Morales M, Catal\u00e1n R, Hern\u00e1ndez-Pedro NY, Rios-Garcia E, Ramos-Ram\u00edrez M, Arrieta O. LKB1 loss assessed by immunohistochemistry as a prognostic marker to first-line therapy in advanced non-small-cell lung cancer. Curr Oncol. 2022;30(1):333\u201343.","journal-title":"Curr Oncol"},{"issue":"2019","key":"2608_CR57","doi-asserted-by":"publisher","first-page":"8730816","DOI":"10.1155\/2019\/8730816","volume":"31","author":"F Ciccarese","year":"2019","unstructured":"Ciccarese F, Zulato E, Indraccolo S. LKB1\/AMPK pathway and drug response in cancer: a therapeutic perspective. Oxid Med Cell Longev. 2019;31(2019):8730816. https:\/\/doi.org\/10.1155\/2019\/8730816.","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"2608_CR58","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/ijms20081874","volume":"20","author":"L Bonanno","year":"2019","unstructured":"Bonanno L, Zulato E, Pavan A, Attili I, Pasello G, Conte P, Indraccolo S. LKB1 and tumor metabolism: the interplay of immune and angiogenic microenvironment in lung cancer. Int J Mol Sci. 2019;20(8):1874. https:\/\/doi.org\/10.3390\/ijms20081874.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2608_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121\u201335. https:\/\/doi.org\/10.1038\/nrm.2017.95.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2608_CR60","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/cas.13333","volume":"108","author":"J Takita","year":"2017","unstructured":"Takita J. The role of anaplastic lymphoma kinase in pediatric cancers. Cancer Sci. 2017;108(10):1913\u201320. https:\/\/doi.org\/10.1111\/cas.13333.","journal-title":"Cancer Sci"},{"issue":"1","key":"2608_CR61","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","volume":"17","author":"B Golding","year":"2018","unstructured":"Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52. https:\/\/doi.org\/10.1186\/s12943-018-0810-4.","journal-title":"Mol Cancer"},{"issue":"3","key":"2608_CR62","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/modpathol.2011.215","volume":"25","author":"L Cheng","year":"2012","unstructured":"Cheng L, Alexander RE, MacLennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S. Molecular pathology of lung cancer: key to personalized medicine. ModernPathology. 2012;25(3):347\u201369. https:\/\/doi.org\/10.1038\/modpathol.2011.215.","journal-title":"ModernPathology"},{"key":"2608_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.critrevonc.2019.02.006","volume":"136","author":"G Rosas","year":"2019","unstructured":"Rosas G, Ruiz R, Araujo JM, Pinto JA, Mas L. ALK rearrangements: biology, detection and opportunities of therapy in non-small cell lung cancer. Crit Rev Oncol\/Hematol. 2019;136:48\u201355. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.006.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"2608_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.02.022","author":"NK Jha","year":"2022","unstructured":"Jha NK, Arfin S, Jha SK, Kar R, Dey A, Gundamaraju R, Ashraf GM, Gupta PK, Dhanasekaran S, Abomughaid MM, Das SS. Re-establishing the comprehension of phytomedicine and nanomedicine in inflammation-mediated cancer signaling. Semin Cancer Biol. 2022. https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.022.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2608_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.34172\/apb.2023.003","volume":"13","author":"S Ghareghomi","year":"2023","unstructured":"Ghareghomi S, Atabaki V, Abdollahzadeh N, Ahmadian S, Hafez GS. Bioactive PI3-kinase\/Akt\/mTOR inhibitors in targeted lung cancer therapy. Adv Pharm Bull. 2023;13(1):24\u201335. https:\/\/doi.org\/10.34172\/apb.2023.003.","journal-title":"Adv Pharm Bull"},{"key":"2608_CR66","doi-asserted-by":"publisher","first-page":"205031212211323","DOI":"10.1177\/20503121221132352","volume":"10","author":"J Barbar","year":"2022","unstructured":"Barbar J, Armach M, Hodroj MH, Assi S, El Nakib C, Chamseddine N, Assi HI. Emerging genetic biomarkers in lung adenocarcinoma. SAGE Open Med. 2022;10:20503121221132350.","journal-title":"SAGE Open Med"},{"issue":"8","key":"2608_CR67","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrg1879","volume":"7","author":"JA Engelman","year":"2006","unstructured":"Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606\u201319.","journal-title":"Nat Rev Genet"},{"issue":"75","key":"2608_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2019.100657","volume":"1","author":"MK Rathinaswamy","year":"2020","unstructured":"Rathinaswamy MK, Burke JE. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease. Adv Biol Regul. 2020;1(75): 100657.","journal-title":"Adv Biol Regul"},{"issue":"7","key":"2608_CR69","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1541-7786.MCR-09-0068","volume":"7","author":"A Denley","year":"2009","unstructured":"Denley A, Gymnopoulos M, Kang S, Mitchell C, Vogt PK. Requirement of phosphatidylinositol (3, 4, 5) trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res. 2009;7(7):1132\u20138.","journal-title":"Mol Cancer Res"},{"key":"2608_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2608_CR71","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/138920207782446160","volume":"8","author":"A Arcaro","year":"2007","unstructured":"Arcaro A, Guerreiro AS. The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics. 2007;8(5):271\u2013306.","journal-title":"Curr Genomics"},{"issue":"2","key":"2608_CR72","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/cells3020304","volume":"3","author":"IN Maruyama","year":"2014","unstructured":"Maruyama IN. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cells. 2014;3(2):304\u201330.","journal-title":"Cells"},{"issue":"1","key":"2608_CR73","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","volume":"69","author":"SR Hubbard","year":"2000","unstructured":"Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem. 2000;69(1):373\u201398.","journal-title":"Annu Rev Biochem"},{"issue":"38","key":"2608_CR74","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S0959-8049(02)80597-4","volume":"1","author":"T Pawson","year":"2002","unstructured":"Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer. 2002;1(38):S3-10.","journal-title":"Eur J Cancer"},{"issue":"30","key":"2608_CR75","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.2174\/13816128113199990343","volume":"19","author":"C Schettino","year":"2013","unstructured":"Schettino C, Bareschino MA, Sacco PC, Maione P, Rossi A, Casaluce F, Sgambato A, Gridelli C. New molecular targets in the treatment of NSCLC. Curr Pharm Des. 2013;19(30):5333\u201343.","journal-title":"Curr Pharm Des"},{"issue":"113","key":"2608_CR76","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.03.015","volume":"1","author":"DR McGowan","year":"2019","unstructured":"McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S. Buparlisib with thoracic radiotherapy and its effect on tumor hypoxia: a phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer. 2019;1(113):87\u201395.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2608_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17(1):1\u20134.","journal-title":"Mol Cancer"},{"key":"2608_CR78","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00018-008-7440-8","volume":"65","author":"MJ Wieduwilt","year":"2008","unstructured":"Wieduwilt MJ, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65:1566\u201384.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2608_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01503-1","volume":"21","author":"S Raj","year":"2022","unstructured":"Raj S, Kesari KK, Kumar A, Rathi B, Sharma A, Gupta PK, Jha SK, Jha NK, Slama P, Roychoudhury S, Kumar D. Molecular mechanism (s) of regulation (s) of c-MET\/HGF signaling in head and neck cancer. Mol Cancer. 2022;21(1):1\u20136.","journal-title":"Mol Cancer"},{"key":"2608_CR80","first-page":"2379","volume":"1","author":"Y Feng","year":"2022","unstructured":"Feng Y, Yang Z, Xu X. C-met: a promising therapeutic target in bladder cancer. Cancer Manag Res. 2022;1:2379\u201388.","journal-title":"Cancer Manag Res"},{"issue":"11","key":"2608_CR81","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0452","volume":"16","author":"AA Rucki","year":"2017","unstructured":"Rucki AA, Xiao Q, Muth S, Chen J, Che X, Kleponis J, Sharma R, Anders RA, Jaffee EM, Zheng L. Dual inhibition of Hedgehog and c-Met pathways for pancreatic cancer treatment. Mol Cancer Ther. 2017;16(11):2399\u2013409.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2608_CR82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbcan.2016.04.001","volume":"1865","author":"A Kazanets","year":"2016","unstructured":"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta Rev Cancer. 2016;1865(2):275\u201388.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"2608_CR83","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2741\/4847","volume":"25","author":"S Ilango","year":"2020","unstructured":"Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci-Landmark. 2020;25(6):1058\u2013109.","journal-title":"Front Biosci-Landmark"},{"issue":"1","key":"2608_CR84","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","volume":"38","author":"LD Moore","year":"2013","unstructured":"Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23\u201338.","journal-title":"Neuropsychopharmacology"},{"issue":"787","key":"2608_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108365","volume":"1","author":"AW Caliri","year":"2021","unstructured":"Caliri AW, Tommasi S, Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res\/Rev Mutat Res. 2021;1(787): 108365.","journal-title":"Mutat Res\/Rev Mutat Res"},{"issue":"13","key":"2608_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878740","volume":"20","author":"S Yang","year":"2022","unstructured":"Yang S, Huang Y, Zhao Q. Epigenetic alterations and inflammation as emerging use for the advancement of treatment in non-small cell lung cancer. Front Immunol. 2022;20(13): 878740.","journal-title":"Front Immunol"},{"issue":"19","key":"2608_CR87","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.3390\/ijms221910592","volume":"22","author":"PC Teng","year":"2021","unstructured":"Teng PC, Liang Y, Yarmishyn AA, Hsiao YJ, Lin TY, Lin TW, Teng YC, Yang YP, Wang ML, Chien CS, Luo YH. RNA modifications and epigenetics in modulation of lung cancer and pulmonary diseases. Int J Mol Sci. 2021;22(19):10592.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2608_CR88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.","journal-title":"J Hematol Oncol"},{"issue":"70","key":"2608_CR89","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-380866-0.60002-2","volume":"1","author":"M Kulis","year":"2010","unstructured":"Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;1(70):27\u201356.","journal-title":"Adv Genet"},{"key":"2608_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112960","volume":"28","author":"S Fu","year":"2023","unstructured":"Fu S, Debes JD, Boonstra A. DNA methylation markers in the detection of hepatocellular carcinoma. Eur J Cancer. 2023;28: 112960.","journal-title":"Eur J Cancer"},{"issue":"10149","key":"2608_CR91","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(18)31268-6","volume":"392","author":"Y Dor","year":"2018","unstructured":"Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and medicine. Lancet. 2018;392(10149):777\u201386.","journal-title":"Lancet"},{"issue":"121","key":"2608_CR92","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biochi.2015.12.018","volume":"1","author":"S Bhat","year":"2016","unstructured":"Bhat S, Kabekkodu SP, Noronha A, Satyamoorthy K. Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie. 2016;1(121):298\u2013311.","journal-title":"Biochimie"},{"issue":"5","key":"2608_CR93","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019133","volume":"6","author":"E Li","year":"2014","unstructured":"Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6(5): a019133.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2608_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147487","volume":"19","author":"A Sergeeva","year":"2023","unstructured":"Sergeeva A, Davydova K, Perenkov A, Vedunova M. Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology. Gene. 2023;19: 147487.","journal-title":"Gene"},{"issue":"21","key":"2608_CR95","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.3390\/cancers13215433","volume":"13","author":"J Smith","year":"2021","unstructured":"Smith J, Banerjee R, Waly R, Urbano A, Gimenez G, Day R, Eccles MR, Weeks RJ, Chatterjee A. Locus-specific DNA methylation editing in melanoma cell lines using a CRISPR-based system. Cancers. 2021;13(21):5433.","journal-title":"Cancers"},{"issue":"7943","key":"2608_CR96","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, Fox-Fisher I, Shabi-Porat S, Hecht M, Pelet T, Moss J. A DNA methylation atlas of normal human cell types. Nature. 2023;613(7943):355\u201364.","journal-title":"Nature"},{"key":"2608_CR97","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.semcancer.2017.09.005","volume":"51","author":"M Duruisseaux","year":"2018","unstructured":"Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications. Semin Cancer Biol. 2018;51:116\u201328.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2608_CR98","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/pcmedi\/pbz003","volume":"2","author":"L Li","year":"2019","unstructured":"Li L, Fu K, Zhou W, Snyder M. Applying circulating tumor DNA methylation in the diagnosis of lung cancer. Precis Clin Med. 2019;2(1):45\u201356.","journal-title":"Precis Clin Med"},{"issue":"5","key":"2608_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195716","volume":"13","author":"RF Walter","year":"2018","unstructured":"Walter RF, Rozynek P, Casjens S, Werner R, Mairinger FD, Speel EJ, Zur Hausen A, Meier S, Wohlschlaeger J, Theegarten D, Behrens T. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer. PLoS ONE. 2018;13(5): e0195716.","journal-title":"PLoS ONE"},{"issue":"10","key":"2608_CR100","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/1078-0432.CCR-11-2797","volume":"18","author":"F de Fraipont","year":"2012","unstructured":"de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin Cancer Res. 2012;18(10):2976\u201386.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2608_CR101","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/17476348.2022.2085091","volume":"16","author":"J Duan","year":"2022","unstructured":"Duan J, Zhong B, Fan Z, Zhang H, Xu M, Zhang X, Sanders YY. DNA methylation in pulmonary fibrosis and lung cancer. Expert Rev Respir Med. 2022;16(5):519\u201328.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"2608_CR102","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/jcm8030414","volume":"8","author":"F Calabrese","year":"2019","unstructured":"Calabrese F, Lunardi F, Pezzuto F, Fortarezza F, Vuljan SE, Marquette C, Hofman P. Are there new biomarkers in tissue and liquid biopsies for the early detection of non-small cell lung cancer? J Clin Med. 2019;8(3):414.","journal-title":"J Clin Med"},{"issue":"2","key":"2608_CR103","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41374-021-00666-7","volume":"102","author":"L Jin","year":"2022","unstructured":"Jin L, Kiang KM, Cheng SY, Leung GK. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O6-methylguanine DNA methyltransferase (MGMT) expression and reactive oxygen species (ROS)-mediated DNA damage in glioblastoma. Lab Invest. 2022;102(2):194\u2013203.","journal-title":"Lab Invest"},{"issue":"4","key":"2608_CR104","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nrc1319","volume":"4","author":"SL Gerson","year":"2004","unstructured":"Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004;4(4):296\u2013307.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2608_CR105","first-page":"261","volume":"9","author":"M Jakopovic","year":"2013","unstructured":"Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front Oncol. 2013;9(3):261.","journal-title":"Front Oncol"},{"key":"2608_CR106","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.gpb.2023.03.006","volume":"21","author":"JA Karlow","year":"2023","unstructured":"Karlow JA, Pehrsson EC, Xing X, Watson M, Devarakonda S, Govindan R, Wang T. Non-small cell lung cancer epigenomes exhibit altered DNA methylation in smokers and never-smokers. Genomics Proteomics, Bioinform. 2023;21:991.","journal-title":"Genomics Proteomics, Bioinform"},{"issue":"8","key":"2608_CR107","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","volume":"1","author":"R Zhao","year":"2016","unstructured":"Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16INK4a) in cancer. EBioMedicine. 2016;1(8):30\u20139.","journal-title":"EBioMedicine"},{"issue":"12","key":"2608_CR108","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-07-4552","volume":"14","author":"R Iwakawa","year":"2008","unstructured":"Iwakawa R, Kohno T, Anami Y, Noguchi M, Suzuki K, Matsuno Y, Mishima K, Nishikawa R, Tashiro F, Yokota J. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR\/KRAS\/p53 mutations in lung adenocarcinoma. Clin Cancer Res. 2008;14(12):3746\u201353.","journal-title":"Clin Cancer Res"},{"key":"2608_CR109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13053-020-00158-7","volume":"19","author":"SH Chan","year":"2021","unstructured":"Chan SH, Chiang J, Ngeow J. CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition. Hereditary Cancer Clin Pract. 2021;19:1\u20139.","journal-title":"Hereditary Cancer Clin Pract"},{"key":"2608_CR110","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2152\/jmi.51.146","volume":"51","author":"N Ohtani","year":"2004","unstructured":"Ohtani N, Yamakoshi K, Takahashi A, Hara E. The p16INK4a-RB pathway: molecular link between cellular senescence and tumor suppression. J Med Invest. 2004;51:146\u201353.","journal-title":"J Med Invest"},{"issue":"11","key":"2608_CR111","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1097\/JTO.0b013e3182a46c0c","volume":"8","author":"KW Tam","year":"2013","unstructured":"Tam KW, Zhang W, Soh J, Stastny V, Chen M, Sun H, Thu K, Rios JJ, Yang C, Marconett CN, Selamat SA. CDKN2A\/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non\u2013small-cell lung cancer. J Thorac Oncol. 2013;8(11):1378\u201388.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2608_CR112","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/ab2f9f","volume":"13","author":"A Campanella","year":"2019","unstructured":"Campanella A, De Summa S, Tommasi S. Exhaled breath condensate biomarkers for lung cancer. J Breath Res. 2019;13(4): 044002.","journal-title":"J Breath Res"},{"issue":"8","key":"2608_CR113","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbagrm.2014.03.001","volume":"1839","author":"SB Rothbart","year":"2014","unstructured":"Rothbart SB, Strahl BD. Interpreting the language of histone and DNA modifications. Biochim Biophys Acta Gene Regul Mech. 2014;1839(8):627\u201343.","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"issue":"7","key":"2608_CR114","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018762","volume":"6","author":"R Marmorstein","year":"2014","unstructured":"Marmorstein R, Zhou MM. Writers and readers of histone acetylation: structure, mechanism, and inhibition. Cold Spring Harb Perspect Biol. 2014;6(7): a018762.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"2608_CR115","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1101\/gad.12.5.599","volume":"12","author":"K Struhl","year":"1998","unstructured":"Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12(5):599\u2013606.","journal-title":"Genes Dev"},{"issue":"1","key":"2608_CR116","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327.","journal-title":"Cell"},{"issue":"2","key":"2608_CR117","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.molcel.2012.10.025","volume":"49","author":"MA McBrian","year":"2013","unstructured":"McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K, Hong CS, Christofk HR, Vogelauer M, Seligson DB, Kurdistani SK. Histone acetylation regulates intracellular pH. Mol Cell. 2013;49(2):310\u201321.","journal-title":"Mol Cell"},{"issue":"4","key":"2608_CR118","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol. 2016;8(4): a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"8","key":"2608_CR119","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018747","volume":"6","author":"X Cheng","year":"2014","unstructured":"Cheng X. Structural and functional coordination of DNA and histone methylation. Cold Spring Harb Perspect Biol. 2014;6(8): a018747.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5","key":"2608_CR120","doi-asserted-by":"publisher","first-page":"558","DOI":"10.2174\/1568009611313050007","volume":"13","author":"X Tian","year":"2013","unstructured":"Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013;13(5):558\u201379.","journal-title":"Curr Cancer Drug Targets"},{"key":"2608_CR121","first-page":"2019","volume":"12","author":"YX Shi","year":"2019","unstructured":"Shi YX, Sheng DQ, Cheng L, Song XY. Current landscape of epigenetics in lung cancer: focus on the mechanism and application. J Oncol. 2019;12:2019.","journal-title":"J Oncol"},{"issue":"22","key":"2608_CR122","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.3390\/ijms20225573","volume":"20","author":"X Zhang","year":"2019","unstructured":"Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, Shen F. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2608_CR123","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cancers13071522","volume":"13","author":"PI Turai","year":"2021","unstructured":"Turai PI, Ny\u00edr\u0151 G, Butz H, Pat\u00f3cs A, Igaz P. MicroRNAs, long non-coding RNAs, and circular RNAs: potential biomarkers and therapeutic targets in pheochromocytoma\/paraganglioma. Cancers. 2021;13(7):1522.","journal-title":"Cancers"},{"key":"2608_CR124","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.2147\/OTT.S178431","volume":"13","author":"T Lu","year":"2018","unstructured":"Lu T, Wang Y, Chen D, Liu J, Jiao W. Potential clinical application of lncRNAs in non-small cell lung cancer. Onco Targets Ther. 2018;13:8045\u201352.","journal-title":"Onco Targets Ther"},{"key":"2608_CR125","volume":"30","author":"AA Bhat","year":"2023","unstructured":"Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Kazmi I, Alzarea SI, Saleem S, Samuel VP, Gubbiyappa SK. MALAT1: a key regulator in lung cancer pathogenesis and therapeutic targeting. Pathol-Res Pract. 2023;30: 154991.","journal-title":"Pathol-Res Pract"},{"key":"2608_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26607","author":"A Uddin","year":"2018","unstructured":"Uddin A, Chakraborty S. Role of miRNAs in lung cancer. J Cell Physiol. 2018. https:\/\/doi.org\/10.1002\/jcp.26607.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2608_CR127","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2010.08.013","volume":"18","author":"ME Hatley","year":"2010","unstructured":"Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, Van Rooij E, Olson EN. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282\u201393.","journal-title":"Cancer Cell"},{"key":"2608_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154053","volume":"29","author":"AS Doghish","year":"2022","unstructured":"Doghish AS, Ismail A, Elrebehy MA, Elbadry AM, Mahmoud HH, Farouk SM, Serea GA, Elghany RA, El-Halwany KK, Alsawah AO, Dewidar HI. A study of miRNAs as cornerstone in lung cancer pathogenesis and therapeutic resistance: a focus on signaling pathways interplay. Pathol-Res Pract. 2022;29: 154053.","journal-title":"Pathol-Res Pract"},{"issue":"4","key":"2608_CR129","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrm.2015.32","volume":"17","author":"LL Chen","year":"2016","unstructured":"Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205\u201311.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"2608_CR130","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.7150\/ijbs.22531","volume":"13","author":"M Wang","year":"2017","unstructured":"Wang M, Yu F, Wu W, Zhang Y, Chang W, Ponnusamy M, Wang K, Li P. Circular RNAs: a novel type of non-coding RNA and their potential implications in antiviral immunity. Int J Biol Sci. 2017;13(12):1497.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2608_CR131","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/wrna.1294","volume":"6","author":"I Chen","year":"2015","unstructured":"Chen I, Chen CY, Chuang TJ. Biogenesis, identification, and function of exonic circular RNAs. Wiley Interdiscip Rev: RNA. 2015;6(5):563\u201379.","journal-title":"Wiley Interdiscip Rev: RNA"},{"issue":"3","key":"2608_CR132","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, Zhong G, Yu B, Hu W, Dai L, Zhu P. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256\u201364.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"2608_CR133","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-017-0663-2","volume":"16","author":"S Meng","year":"2017","unstructured":"Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P, Wu M. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol Cancer. 2017;16(1):1\u20138.","journal-title":"Mol Cancer"},{"key":"2608_CR134","first-page":"171","volume-title":"Circular RNAs: biogenesis and functions","author":"L Xia","year":"2018","unstructured":"Xia L, Song M, Sun M, Wang F, Yang C. Circular RNAs as biomarkers for cancer. In: Circular RNAs: biogenesis and functions. Singapore: Springer; 2018. p. 171\u201387."},{"issue":"5","key":"2608_CR135","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"6","key":"2608_CR136","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.7150\/jca.31406","volume":"11","author":"L Chang","year":"2020","unstructured":"Chang L, Fang S, Gu W. The molecular mechanism of metabolic remodeling in lung cancer. J Cancer. 2020;11(6):1403.","journal-title":"J Cancer"},{"issue":"12","key":"2608_CR137","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nrc2540","volume":"8","author":"JA Bertout","year":"2008","unstructured":"Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2608_CR138","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","volume":"30","author":"J Kim","year":"2019","unstructured":"Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 2019;30(3):434\u201346.","journal-title":"Cell Metab"},{"key":"2608_CR139","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11033-015-3858-x","volume":"42","author":"R Courtnay","year":"2015","unstructured":"Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42:841\u201351.","journal-title":"Mol Biol Rep"},{"issue":"3191","key":"2608_CR140","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309\u201314.","journal-title":"Science"},{"key":"2608_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40170-015-0128-2","volume":"3","author":"CS Ahn","year":"2015","unstructured":"Ahn CS, Metallo CM. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 2015;3:1.","journal-title":"Cancer Metab"},{"key":"2608_CR142","volume":"26","author":"PK Arnold","year":"2022","unstructured":"Arnold PK, Finley LW. Regulation and function of the mammalian tricarboxylic acid cycle. J Biol Chem. 2022;26: 102838.","journal-title":"J Biol Chem"},{"issue":"9","key":"2608_CR143","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3389\/fonc.2019.01215","volume":"15","author":"K Vanhove","year":"2019","unstructured":"Vanhove K, Graulus GJ, Mesotten L, Thomeer M, Derveaux E, Noben JP, Guedens W, Adriaensens P. The metabolic landscape of lung cancer: new insights in a disturbed glucose metabolism. Front Oncol. 2019;15(9):1215.","journal-title":"Front Oncol"},{"issue":"2","key":"2608_CR144","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bbcan.2015.08.002","volume":"1856","author":"H Lemjabbar-Alaoui","year":"2015","unstructured":"Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta Rev Cancer. 2015;1856(2):189\u2013210.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"2608_CR145","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.12-2359","volume":"143","author":"JA Howington","year":"2013","unstructured":"Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143(5):e278S-313S.","journal-title":"Chest"},{"issue":"6","key":"2608_CR146","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","volume":"28","author":"SG da Cunha","year":"2011","unstructured":"da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;28(6):49\u201369.","journal-title":"Annu Rev Pathol"},{"issue":"9722","key":"2608_CR147","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","volume":"375","author":"NSCLC Meta-analyses Collaborative Group","year":"2010","unstructured":"NSCLC Meta-analyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267\u201377.","journal-title":"Lancet"},{"issue":"15","key":"2608_CR148","doi-asserted-by":"publisher","first-page":"e120858","DOI":"10.1172\/jci.insight.120858","volume":"3","author":"S Pakkala","year":"2018","unstructured":"Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018;3(15):e120858.","journal-title":"JCI Insight"},{"issue":"8","key":"2608_CR149","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1158\/0008-5472.CAN-12-3932","volume":"73","author":"JG Aerts","year":"2013","unstructured":"Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Can Res. 2013;73(8):2381\u20138.","journal-title":"Can Res"},{"issue":"3","key":"2608_CR150","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","volume":"23","author":"M Singh","year":"2018","unstructured":"Singh M, Jadhav HR. Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discovery Today. 2018;23(3):745\u201353.","journal-title":"Drug Discovery Today"},{"issue":"9","key":"2608_CR151","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3390\/antiox10091455","volume":"10","author":"BP George","year":"2021","unstructured":"George BP, Chandran R, Abrahamse H. Role of phytochemicals in cancer chemoprevention: insights. Antioxidants. 2021;10(9):1455.","journal-title":"Antioxidants"},{"key":"2608_CR152","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10555-010-9239-y","volume":"29","author":"L Shu","year":"2010","unstructured":"Shu L, Cheung KL, Khor TO, Chen C, Kong AN. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev. 2010;29:483\u2013502.","journal-title":"Cancer Metastasis Rev"},{"key":"2608_CR153","first-page":"282570","volume":"2012","author":"K Sak","year":"2012","unstructured":"Sak K. Chemotherapy and dietary phytochemical agents. Chemother Res Pract. 2012;2012:282570.","journal-title":"Chemother Res Pract"},{"issue":"3","key":"2608_CR154","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/nu15030491","volume":"15","author":"Y Ding","year":"2023","unstructured":"Ding Y, Hou R, Yu J, Xing C, Zhuang C, Qu Z. Dietary phytochemicals as potential chemopreventive agents against tobacco-induced lung carcinogenesis. Nutrients. 2023;15(3):491.","journal-title":"Nutrients"},{"issue":"5","key":"2608_CR155","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3390\/diseases12050093","volume":"12","author":"P Mohanty","year":"2024","unstructured":"Mohanty P, Pande B, Acharya R, Bhaskar LV, Verma HK. Unravelling the triad of lung cancer, drug resistance, and metabolic pathways. Diseases. 2024;12(5):93.","journal-title":"Diseases"},{"issue":"4","key":"2608_CR156","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/cancers14040961","volume":"14","author":"PH Hoang","year":"2022","unstructured":"Hoang PH, Landi MT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors. Cancers. 2022;14(4):961.","journal-title":"Cancers"},{"issue":"3","key":"2608_CR157","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells. 2022;11(3):320.","journal-title":"Cells"},{"issue":"3","key":"2608_CR158","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2174\/1389201011314030007","volume":"14","author":"CM Shoshan","year":"2013","unstructured":"Shoshan CM. Potentiation of anti-cancer treatment by modulators of energy metabolism. Curr Pharm Biotechnol. 2013;14(3):313\u201330.","journal-title":"Curr Pharm Biotechnol"},{"issue":"42","key":"2608_CR159","doi-asserted-by":"publisher","first-page":"72544","DOI":"10.18632\/oncotarget.19881","volume":"8","author":"L MacDonagh","year":"2017","unstructured":"MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Breen E, Gray SG, Nicholson S, Leonard N, Ryan R, Young V, O\u2019Leary JJ. Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. Oncotarget. 2017;8(42):72544.","journal-title":"Oncotarget"},{"issue":"428","key":"2608_CR160","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2018.04.008","volume":"1","author":"L MacDonagh","year":"2018","unstructured":"MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O\u2019Byrne KJ, Barr MP. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;1(428):117\u201326.","journal-title":"Cancer Lett"},{"issue":"11","key":"2608_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.689131","volume":"26","author":"G Catara","year":"2021","unstructured":"Catara G, Colanzi A, Spano D. Combinatorial strategies to target molecular and signaling pathways to disarm cancer stem cells. Front Oncol. 2021;26(11): 689131.","journal-title":"Front Oncol"},{"key":"2608_CR162","unstructured":"Darvish M, Trask R, Tallon P, Khansari M, Ren L, Hershman M, Yousefi B. AI-enabled lung cancer prognosis. arXiv preprint arXiv:2402.09476. 2024 Feb 12."},{"issue":"34","key":"2608_CR163","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1073\/pnas.1718942115","volume":"115","author":"J Han","year":"2018","unstructured":"Han J, Jentzen A, Weinan E. Solving high-dimensional partial differential equations using deep learning. Proc Natl Acad Sci USA. 2018;115(34):8505\u201310.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02608-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:19:14Z","timestamp":1741270754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02608-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,2]]},"references-count":163,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02608-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,2]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"61"}}